Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life
Acta Haematologica · 10.01.2025 · 148 (6) · 708-721
DOI: 10.1159/000542562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 10.01.2025. Verfasst von Joon Ho Moon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Kore…. Hauptthemen laut MEDLINE: Quality of Life, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study aimed to analyze the survival outcomes and adverse events (AEs) associated with the long-term use of tyrosine kinase inhibitors (TKIs) and to assess health-related quality of life (HRQoL) in patients with chronic myeloid leukemia (CML).
Methods
Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed.
Results
No significant differences in survival were observed based on the number of different TKIs the patients received (p = 0.301) or the sequence of TKIs used (p = 0.770). Among 182 patients treated with nilotinib, 25 experienced cardiovascular events (CVEs). After 10 years of nilotinib treatment, CVEs occurred in 55.2% of patients with ≥2 vascular risk factors. Pleural effusion was observed in 27 of 78 dasatinib-treated patients. In terms of HRQoL, patients treated with nilotinib generally reported higher satisfaction levels than did those treated with imatinib or dasatinib. When stratified by age or duration of TKI treatment, patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea, posgary@gmail.com.
Zitieren
APA
Moon, J. H., Cho, H. J., Baek, D. W., Kim, J., Jang, Y. E., Lee, Y., Moon, J. H., & Sohn, S. K. (2025). Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life. Acta Haematologica, 148(6), 708-721. https://doi.org/10.1159/000542562
Vancouver
Moon JH, Cho HJ, Baek DW, Kim J, Jang YE, Lee Y, et al. Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life. Acta Haematologica. 2025;148(6):708-721. doi:10.1159/000542562
BibTeX
@article{Moon2025,
author = {Moon, Joon Ho and Cho, Hee Jeong and Baek, Dong Won and Kim, Juhyung and Jang, Young Eun and Lee, Yunji and Moon, Joon Ho and Sohn, Sang Kyun},
title = {Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life},
journal = {Acta Haematologica},
year = {2025},
volume = {148},
number = {6},
pages = {708--721},
doi = {10.1159/000542562}
}
EUVIMED